IGTROPURE (IGF-1 Long R3) by Meditech is a pharmaceutical-grade recombinant Insulin-like Growth Factor-1 Long R3 lyophilized injectable peptide formulation at 1000 mcg per vial. IGF-1 Long R3 is a bioengineered analogue of endogenous IGF-1 incorporating specific structural modifications that significantly extend its plasma half-life and biological activity relative to native IGF-1, making it a subject of sustained research interest in growth factor pharmacology, cellular biology, and anabolic peptide research literature.
 
✔ Key Research Insights
Studied for its role in stimulating muscle cell hyperplasia and hypertrophy via IGF-1 receptor activation in research subjects, with documented effects on satellite cell proliferation and myofibrillar protein synthesis in comparative growth factor research
Investigated for its extended plasma half-life relative to native IGF-1, attributed to structural modifications at positions 1 and 3 of the peptide chain that reduce insulin-like growth factor binding protein (IGFBP) affinity and DPP-IV enzymatic degradation in pharmacokinetic research
Researched for its influence on nutrient partitioning and amino acid transport into muscle tissue, with documented effects on cellular glucose and amino acid uptake efficiency in growth factor pharmacology observations
Examined for its effects on fat metabolism parameters, with IGF-1 receptor-mediated lipolytic activity documented in adipose tissue research across comparative growth factor literature
Documented for its influence on recovery markers and muscle protein catabolism inhibition in research subject populations across peptide pharmacology research protocols
Manufactured by Meditech to pharmaceutical-grade recombinant peptide purity and lyophilized formulation standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: IGTROPURE
Molecule: Recombinant IGF-1 Long R3
Concentration: 1000 mcg per vial
Appearance: Lyophilized white powder
Form: Injectable peptide requiring reconstitution prior to administration
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
IGF-1 Long R3 is a recombinant analogue of endogenous insulin-like growth factor-1 (IGF-1), incorporating two key structural modifications relative to the native IGF-1 molecule: substitution of arginine for glutamic acid at position 3 and addition of a 13-amino acid N-terminal extension. These modifications collectively reduce the binding affinity of IGF-1 Long R3 for insulin-like growth factor binding proteins (IGFBPs) — the primary plasma carrier proteins responsible for sequestering and inactivating circulating IGF-1 in research subjects — resulting in a substantially higher proportion of unbound, biologically active peptide in systemic circulation. The consequent extended plasma half-life, documented in comparative pharmacokinetic research at approximately 20–30 hours relative to the 12–15 minute half-life of native IGF-1, enables prolonged IGF-1 receptor activation across target tissues between administrations. In muscle tissue, IGF-1 receptor binding activates the PI3K/Akt/mTOR intracellular signaling cascade documented in growth factor research as a primary regulator of muscle protein synthesis, satellite cell activation, and myofibrillar hypertrophy. Independent receptor-mediated effects on glucose and amino acid transport into muscle cells have additionally been documented in nutrient partitioning research literature. In adipose tissue, IGF-1 receptor activation has been investigated for lipolytic signaling effects, contributing to the compound's documented influence on body composition parameters in research subject populations. Reconstitution with bacteriostatic or acetic acid solution is standard protocol prior to subcutaneous administration in documented research settings.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade recombinant peptide purity and lyophilized formulation standards
Bioengineered IGF-1 analogue with a pharmacokinetically distinct extended half-life profile relative to native IGF-1, attributed to IGFBP binding reduction and enzymatic degradation resistance documented in comparative growth factor pharmacokinetic research
Broad anabolic research profile spanning muscle protein synthesis, satellite cell activation, nutrient partitioning, and lipolytic signaling pathways documented across growth factor pharmacology literature
Available in lyophilized vial format at 1000 mcg per vial, requiring reconstitution prior to subcutaneous administration per standard peptide research protocols
Widely referenced in growth factor pharmacology and anabolic peptide research literature under the IGF-1 Long R3 and recombinant IGF-1 designations